VolitionRx Signs a Global Sales and Distribution Agreement with Active Motif for its new RUO kits
VolitionRx Limited Schedules First Quarter 2018 Earnings Conference Call and Business Update
VolitionRx Announces Closing of $8.4 Million Public Offering of Common Stock
VolitionRx Announces Pricing of $8.4 Million Public Offering of Common Stock
VolitionRx Announces Proposed Underwritten Public Offering of Common Stock
VolitionRx Appoints Harvard Professor, Dr. Lee-Jen Wei to Its Scientific Advisory Board
VolitionRX Limited Announces Full Fiscal Year 2017 Financial Results and Business Update
VolitionRx Limited Schedules Full Year 2017 Earnings Conference Call and Business Update
VolitionRx Limited Announces Interim Results from 680-Subject Clinical Trial in Colorectal Cancer
VolitionRX Announces the Successful Conclusion of the Logistics and Pathway Design Study Conducted in Denmark.
